Index

Abatacept 476
accelerated approval 226, 228, 239
acetylcholine receptor antibodies, muscle-type 624
ACT see Avonex Combination Trial
ACTH see adrenocorticotropic hormone
activator protein-1 (API) 419
active-control trials 269 see also comparative effectiveness studies
activity, disease conventional MRI measures 95–96, 97, 98, 199–200 effects of neutralizing antibodies 292, 293 monitoring, in clinical practice 590–591 subclinical 1
acupuncture 567–568
acute attacks of CNS demyelinating disease plasma exchange 455–457 see also relapse(s), acute
acute disseminated encephalomyelitis (ADEM) 23 differential diagnosis 632 plasma exchange 455–457, 459
acute myeloid leukemia (AML), mitoxantrone-related 351, 588
adaptive compensation see compensation, adaptive
adaptive randomization 255–256
adaptive study designs 257–258 add-on trials 269
ADEM see acute disseminated encephalomyelitis
adenosine deaminase (ADA) 358 deficiency 358
adrenocorticotropic hormone (ACTH) cyclophosphamide therapy with 436–437 fatigue and 657 therapy 420–421 adverse effects monitoring see safety monitoring pharmacogenomics approach 275 urologic 677 see also under specific drugs affective disorders pediatric MS 639–640 see also depression AFFIRM study 333–335, 586–587 adverse events 334–335, 587 anti-natalizumab antibodies 294, 335, 587 health-related quality of life outcomes 86–87 neuropsychological effects 67 use of MSFC 63
African Americans, prognosis 49–51 age at onset of MS prognostic significance 49, 50 temporal changes 46–47 aging, brain volume changes 134 AIMS trial 447 albumin, placebo use 451 albuterol (salbutamol) 477 alemtuzumab 393–397 adverse effects 395–397 antibodies 295, 396–397 biology 393–394 clinical trials 394–395 effects on B cells 484 hematopoietic stem cell transplantation 511, 514 history and development 393 neuroprotective effects 395, 540 non-binding variant (SM3) 397 thyroid dysfunction 396, 720 Alert Reports 226 ALLEGRO trial 408 allergic reactions see hypersensitivity reactions alpha lipoid acid (lioid acid) 366, 369 α1 adrenergic blockers 683, 684 αβ1 integrin (VLA-4) 293–294, 330 antagonist see natalizumab functions 27, 330 methylprednisolone actions 419 α4β1 integrin 330 altered peptide ligands (APLs) 24, 247 glatiramer acetate as 277, 316, 317, 474 alternative therapies see complementary and alternative medicine amantadine 720 fatigue 658, 659 neuropsychological effects 68, 70 Ambulation Index 63, 726 amnorrhea, chemotherapy-induced (CIA) 351–352, 588 American Society for Apheresis (ASFA), recommendations 454, 455 4-aminopyridine 557 in cognitive dysfunction 68, 70 extended release formulation see dalfampridine studies in MS 558 amitriptyline 711 AMPA/kainate antagonists 541 l-amphetamine sulfate 68, 69 Ampyra see dalfampridine amyloid precursor protein (APP) 12 AN100226m 331 humanized see natalizumab anesthetic agents, spasticity 670 angioplasty, cerebrospinal venous 577–578 see also liberation procedure angiotensin-converting enzyme (ACE) inhibitors 461 animal models fingolimod studies 376 hematopoietic stem cell transplantation 510–511 NMO-IgG studies 620–621 sex hormones 499–501 teriflunomide studies 411 see also experimental autoimmune encephalomyelitis ankle foot orthoses (AFO) 727 anti-alemtuzumab antibodies 295, 396–397 anti-aquaporin-4 antibodies (NMO/AQP4-IgG) 458, 614, 616–621 binding patterns 616 cancer-related death 624–625 CSF 625 disease severity and 617–618 evidence for pathogenic role 618–621 immune target 617 immunoadsabs 617 prediction of relapse 617, 621 prognostic value 617 removal by plasma exchange 460 anti-CD3 antibody 476 anti-CD4 antibody 476
anti-CD20 antibodies 486–490
mechanisms of action
490–491
see also ocrelizumab; ofatumumab; rituximab
anti-CD154 antibody 476
anti-IFNβ antibodies see under interferon beta
anti-inflammatory therapies, limitations 535–536
anti-melanin antibodies 28, 491–492
anti-natalizumab antibodies 293–295, 335, 587
anti-neuronal antibodies 151
anti-rituximab antibodies 295, 489
anti-thymocyte globulin (ATG) 511, 513, 514–515
antibodies
beneficial effects 28
to biologic agents see neutralizing antibodies
pathogenic role in MS 27, 28 removal via apheresis 459
see also immunoglobulins; specific types
anticholinergic agents 682–683
anticonvulsants 15, 710–711
antidepressants 699, 703
barriers to use 701
bladder dysfunction 682, 683 neuropsychiatric pain 711
pain with depression 712
selection 700
antiepileptics see anticonvulsants
antigen-presenting cells (APCs) 27
B cells as 492
glatiramer acetate actions 316
mesenchymal stem cell effects 522
statin actions 467
antimuscarinic agents 683
antioxidants 565–567
anxiety
fatigue and 655
pain and 708–709
apheresis 456
adverse effects 460–461
current recommendations 454, 455
mechanism of action 459–460
methods 454–455
see also plasma exchange
apolipoprotein E4 (ApoE4) genotype 105, 274
apoptosis
CD4+ T cells 317
corticosteroid-induced 419
neuronal 16–17
apparent diffusion coefficient (ADC) 187–188
aquaporin-4 (AQP4) 617
antibodies see anti-aquaporin-4 antibodies
effects of NMO-IgG binding 619
gene mutations 616
loss of immunoreactivity 618, 619
arthritis 51
artificial urinary sphincter 686
Azrerra see ofatumumab
Ashworth scale 667
Asia, drug development/approval process 228–229
aspirin 658, 659
assessment tools see measurement tools
assistive/adaptive devices 727
asthma, comorbidity 51
ASTIMS trial 512, 515, 516
astrocytes
effects of NMO-IgG 619
fingolimod actions 375
pathogenic role 27, 28, 338
sphingosine 1-phosphate receptors 372, 375
atacicept 493
ATM-027 475–476
torvastatin 468–469
atopy, CNS 106, 128–143
brain see brain atrophy
clinical significance 138–139, 140
correlation with other MRI markers 136–138
fatigue and 657
gray matter see gray matter (GM) atrophy
labor 201
measurement methods 128–134
comparisons between 133
confounding issues 133–134
deforation-based 131
gray vs. white matter 131–132
manual 129
registration-based 131
segmentation-based 129–131
semi-automated and automated 129
specific regions and lobes 132–133
natural history 134–136
primary progressive MS 135, 136, 606
role in clinical trials 7, 140–143, 202–202
spinal cord see spinal cord atrophy
atropine-like drugs 682–683
augmentation cystoplastic 685
Austrian Immunoglobulin in MS (AIMS) trial 447
autoantigens, T-cell activation 23–24
autoimmune disease
alemtuzumab-induced 396
comorbidity, prognostic significance 51
genetic associations 38, 40
mesenchymal stem cell transplantation 526–527
MS as, strength of hypothesis 20–21
neuromyelitis optica-associated 623–624
rituximab 486
autonomic dysfunction 657–658
autonomy, principle of 265
autoimmune T cells see under T cell(s)
Avonex® see interferon beta-1a (IFNβ-1a), intramuscular
Avonex Combination Trial (ACT) 423–427, 439, 550, 593
axial diffusivity (A) 187
axonal hypothesis for chronic disability 151
axonal loss/pathology 12–13, 15
acute conduction block 150–151
conventional MRI 99, 104
diffusion tensor imaging 189–190
glatiramer acetate studies 318
mechanisms 12–15, 151, 537–539
methods of assessment 536–537
MRS evidence 155
MS–histopathology correlation 155–156
MT imaging 113–114
natural history and treatment aspects 157–159
optical coherence tomography 217–220
prevention see neuroprotection
role in chronic disability 150–151
visual pathway 216–217
axonal swelling 15
azathioprine 438, 439–441
effects on B cells 484
neuromyelitis optica 626
primary progressive MS 608
randomized trials 439, 440
azygous venous system
anatomy 576
angioplasty 577–578
drainage in MS 577
B-cell activating factor (BAFF) 28
B-cell based therapies 483–493
future prospects 493
non-selective 483–486
selective see B-cell depletion
B-cell depletion 485, 486–491
anti-CD20 antibodies 486–490
B cells
antibody-independent functions 490–491, 492–493
as antigen-presenting cells 492
Epstein–Barr virus infection 493
fingolimod actions 374
immune modulators and suppressors affecting 484–486
as immune regulators 492–493
laquinimod actions 406
mesenchymal stem cell effects 521–522
mitoxantrone actions 344–345
neodlympogenesis 493
pathogenic role in MS 491–493
regulation of T cells 25–26
responses in CNS 28–29
see also immune cells; lymphocytes
B7 molecules 24
statin actions 467
therapies targeting 476
back pain, low 707, 708
baclofen 668–669, 711, 720
intrathecal (ITB) 671–672
pediatric MS 639
basiliximab 399
Bayesian analysis 248, 258
Bayesian Risk estimate for Multiple Sclerosis (BREMS) score 248
Bayesian study designs 258
BDNF see brain-derived neurotropic factor
BEAM regimen 512–515
BECOME study 305, 309, 322
behavioral interventions 712
belief networks 248
Belmont Report (1978) 261
BENEFIT study 304, 310
follow-up study 302, 306
benign MS 583, 649
benzodiazepines 669, 711
beta-lactam antibiotics 541
beta-naphthoflavone 542
β2-microglobulin 290
Betaseron® see interferon beta-1b
Betaseron® see interferon beta-1b
BEYOND study 305, 307, 309, 320–321
BG00012 (BG-12) 387, 542
Phase 2 trial 389–390, 391
Phase 3 trials 391 see also dimethyl fumarate
bias
adaptive study designs 258
non-randomized observational trials 235–248, 249
hidden sources 249
sources 246
biologic agents
development and approval of similar 229
neutralizing antibodies see neutralizing antibodies see also specific agents
biological assays
biologic license application (BLA) 226, 239
biomarkers 232, 242
as outcome measures 238–241
conventional, pharmacogenomics and 274
disease progression 41–42
drug development process 233, 238
neuromyelitis optica 616–617
predicting response to therapy see predictive biomarkers
prospective 273
in relation to clinical outcomes 239–241
as surrogate endpoints 239–241
Biomarkers Definitions Working Group 232
biosimilars, development and approval 229
black holes see T1-hypointense lesions
bladder, neural control 676
bladder augmentation, surgical 685
bladder dysfunction 676–686
asymptomatic 679
clinical presentation 677
conservative therapy 682–684
evaluation 677–682
management 682–686
neuroanatomy 676–677
surgical management 684–686
bladder rehabilitation program 684
bladder stimulation 686
bladder stimulators, MRI safety 650
blinding (to treatment assignment) 235, 265
blood-oxygen-level-dependent (BOLD) fMRI 176, 180
blood pressure, fingolimod-induced changes 379
blood–brain barrier (BBB) disruption, MRI 92–93
effects of NMO-IgG 619
immune cell transmigration 22, 26–27
BOLD imaging see blood-oxygen-level-dependent (BOLD) fMRI
bone health 718–719
bone marrow
ablative regimens 511–514
multipotent stromal cells see mesenchymal stem cells suppression, mitoxantrone 352
botulinum toxin (BT) bladder dysfunction 684
pediatric MS 639
spasticity 670–671
brain atrophy 5–6, 142
clinical significance 138–140, 606
correlation with other MRI markers 136–138
effects of immunomodulatory drugs 355
fatigue and 657
IFNβ studies 307, 535
measurement methods 128–134
comparisons between 133
confounding issues 133–134
deformation-based 131
gray vs. white matter 131–132
manual 129
registration-based 131
segmentation-based 129–131
semi-automated and automated 129
specific regions and lobes 132–133
natural history 134–136
pathological significance 536
progression over time 128
regional clinical significance 140
different MS phenotypes 136
measurement methods 132–133
role in clinical trials 7, 140–143, 200
role of inflammatory infiltrates 535
brain-derived neurotropic factor (BDNF) 318
exercise-induced production 540
laquinimod actions 406
brain lesions
MRI-defined see lesions, MRI-defined neuromyelitis optica 621–623
brain parenchymal fraction (BPF) 130
IFNβ studies 307
brain pseudoatrophy 5, 134
clinical trials 142
brain-to-intracranial-cavity ratio (BICCR) 130
brain-to-intracranial cavity volume ratio (BICVR) 130
brain volume factors affecting 133–134, 200
loss seen brain atrophy
measurement methods 128–134
normalization 130, 131
BRAVO trial 408
breast feeding 504
drug safety during 716, 717
MRI safety 650
BREMS score 248
Brief Repeatable Neuropsychological Battery (BRB) 71
bromocriptine 504, 542
bupropion 700
burden of disease
pediatric MS 633
see also T1 burden of disease;
T2 burden of disease
bystander suppression, glatiramer acetate 317, 318
calcium (Ca++), increased axoplasmic 14–15
CAMMS223 trial 295, 395–397
Camphath-IG 393
Camphath-IH 393 see also alemtuzumab
Camphath-IM 393
Canadian MS-BMT trial 514–516
cancer
drug-related secondary see malignancies, secondary paraneoplastic neuromyelitis optica 624–625
candidate susceptibility genes 39
cannabinoids 541, 568–569
bladder dysfunction 683
primary progressive MS 608
spasticity 670
nabas 568–569
capsaicin
intravesical 683–684
topical 711
carbamazepine 15, 710–711
cardiac effects
fingolimod 374, 378–379
mitoxantrone 350–351, 353, 588
CARE-MS trials 395
caregivers, support for 701–702
carnitine 658–659
case-only designs, adjusting for bias 246
Catabetes see clonidine
categories of MS, study design issues 2–3
cathespin S (CTSS) gene 276, 277
cathepsins 537
CD3 472, 476
CD4+ helper T cells 472
anti-CD4 antibody 476
autoreactive 21–22
see also T cell(s), autoreactive
CNS injury 27
cyclophosphamide actions 436
daclizumab actions 399
glatiramer acetate actions 317
laquinimod actions 405

© in this web service Cambridge University Press
www.cambridge.org
Phase 2 trials
clinically definite MS (CDMS)
MRI-defined enhancing lesions
rates of conversion 647
clinically isolated syndromes (CIS) 2
anti-myelin antibodies 492
atorvastatin 468
disease-modifying therapies 593
glatiramer acetate 320, 322, 593
high-dose methylprednisolone 429
IFNβ 302–304, 310, 593
intravenous immunoglobulin 446–447
McDonald criteria 646–648
MRI in clinical practice 646–648
CSN atrophy 134–136, 138
enhancing lesions 97–98,
647 magnetization transfer
117–119 T2-hypointense lesions
101 rates of conversion to MS 647
study design issues 3
see also optic neuritis
clinicaltrials.gov 262
clonazepam 669, 720
clonidine 670
intrathecal 672
closed testing principle 255
co-stimulatory molecules 472
therapies targeting 476
cod liver oil 564–565
coefficient of variation (COV) 129
cognitive behavioral therapy (CBT) 658–659, 699, 712
cognitive dysfunction 66
assessment see neuropsychological (NP) assessment
brain atrophy and 140
depression 696, 698
disease-modifying therapy effects 66–68
fatigue and 655–656
fMRI 74, 180–181
functional imaging 180–181
Ginkgo biloba studies 68, 69,
566–567 heterogeneity 68
MT imaging 117
natural history 65–66
pediatric MS 633, 639
Index

selecting patients at risk for progression 73
symptomatic medication trials 68–70
cognitive fatigability 655–656
cognitive rehabilitation 728
cold therapy 668
combination test approach 258
combination therapies 547–554
in clinical practice 593
rationale 547–548
selected trials 549–550, 553
study designs 548–549
CombInx study 305, 309, 324,
549–550, 593
Committee for Medicinal Products for Human Use (CHMP) 227–228, 340
comorbidities, medical 51–52,
714–721
comparative effectiveness studies
79
relapse end-points 235
resource–poor countries 268
study designs 256, 269
compensation, adaptive 17, 175,
181
functional neuroimaging
181–182
mechanisms 17
see also cortical reorganization, adaptive
complement deposition 491
complementary and alternative medicine (CAM)
562–569, 570
categories 562
definition 562
depression 699
future research 569–570
information resources 569
prevalence of use 562–563
recommendations for patients
570
complex disease, MS as 35–37
compliance, strategies to improve 590
computed tomography (CT), methylprednisolone effects 424–425
computer adaptive testing (CAT) 82–83
conditional error function approach 258
conduction block 150–151, 538
CONFIRM trial 391
confounding 246
adjusting for 246–249
connective tissue disorders
623–624
consent, informed 225–226,
263–264
placebo-controlled trials 267
contrast sensitivity, testing 62–63
Copaxone® see glatiramer acetate
copolymer 1 see glatiramer acetate
copy number variations (CNVs) 42
cortical atrophy/thickness
clinical significance 138, 140
different MS phenotypes 136
measurement 132
cortical lesions
classification 15–16, 165–167
clinical significance 17, 168
conventional MRI 94–95,
166–168
neural compensation 17
pathology 15, 16–17, 165
see also gray matter (GM) pathology
cortical reorganization, adaptive
175
interpretation 181, 182
motor system 179–180
visual areas 180
see also compensation, adaptive
corticospinal tracts (CST) 186,
191
corticosteroids
acute relapses 419–422, 594
imaging studies 424–426
mechanism of action 418–420,
484–486
neuromyelitis optica 625
novel formulations 429
pediatric MS 633, 638
relative potency and biological
activity 419–420
toxicity 427–428
see also methylprednisolone; prednisone
cortisol 503–504
Council for International Organizations of Medical Sciences (CIOMS) 261,
262, 268
Cox proportional hazard model
247
propensity score adjustment
248
creatinine
creatinine/phosphocreatine (Cr)
changes in MS 155
resonances 154
crossover design see deferred
treatment design
CTLA-4 receptor 24
CTLA4 Ig 476
2', 3'-cyclic nucleotide
3'-phosphodiesterase
(CNP) 14
cyclobenzaprine 711
cyclophosphamide (CY; CTX)
436–438
clinical trials 436–437, 440
effects on B cells 484
hematopoietic stem cell
transplantation 513–514
in clinical practice 437–438,
594
in pregnancy and lactation 716
newer uses 438
pediatric MS 637–638
primary progressive MS 608
tolerability and safety 438
cyclosporin A 541
cyproheptadine 670
cystourethrogram, voiding
678–679, 681
cytokines
B cell 492–493
CSF, neuromyelitis optica 623
fish oil supplements and 565
T helper subsets 473
therapies modulating 476–477
cytotoxic agent, mitoxantrone as
344–345
Cytosan see cyclophosphamide
daclozumab 399–403
antibodies 295
clinical development plan 403
clinical trials 399–400, 402
mechanism of action 26,
399–400
safety 402–403
dalfampridine 538, 557–560
adverse effects 558, 560, 720
eyearly studies 558
in clinical practice 560
clinical trials 558–560, 727
in pregnancy and lactation 716
pediatric MS 639
pharmacology and
pharmacokinetics 557–558
see also 4-aminopyridine
Danish IFNβ Study 305, 308
Dantrium® see dantrolene
dantrolene 639, 669–670
darifenacin 683
data and safety monitoring committees 263
dawson’s fingers 574
DDAVP 683–684
DECIDE study 400, 403
deconditioning, physical 658,
709
deep brain stimulators, MRI
safety 650
default mode networks (DFN)
181–182
deferred randomization 256
deferred treatment design 254,
269
DEFINE trial 391
dehydroepiandrosterone (DHEA) 657
demographics of MS, changing
46
demoralization 697
demyelination
cortical matter 15–17
diffusion tensor imaging
189–190
inflammatory
axonal damage 12–13
as therapeutic target 17–18
MT imaging 113–115, 121
pathogenesis of axonal loss
12–15, 150, 538–539
dendritic cells, laquinimod
actions 406
deoxycytidine kinase (DCK) 358
deoxycytidine kinase (DCK): 5'-nucleotidase
(5’-NTase) ratio 358–359
depression 51, 696–703
causes in MS 698, 699, 703
corticosteroid-induced 427
diagnosis 697–698, 702
diagnostic criteria 697
epidemiology and impact on
MS 696–697
fatigue and 655, 697, 698
functional imaging 179
IFNβ-treated patients 585
medications worsening 698
pain associated with 708–709
treatment 712
pediatric MS 639–640
standard of care 701–702
treatment 698–699, 702–703
barriers 700–701
impact on disease course
700
see also antidepressants
desipramine 699–700, 712
Index

Deltro™ see tolerodine
detrusor hyperreflexia (DH) 679–881
conservative therapy 682–684
surgical management 684–686
detrusor hypocontractility/areflexia 680–681, 684
detrusor sphincter dyssynergia (DSD) 680–682
conservative therapy 683–684
surgical management 684–686
developing countries, ethics of research 263, 267–268
Devic’s disease 614
see also neuromyelitis optica
dexamethasone, relapsing MS 422–423
dexrazoxane 353
diabetes 51
diagnosis of MS differential 646
follow-up MRI 648
history 645–646
reduced delays 46
use of MRI 643–648
3, 4-diaminopyridine 68, 70
functional imaging studies 180
diarylpropionitrile (DPN) 501–503
diazepam 669
pediatric MS 639
diclofenac, topical 710–711
diet
low fat 564
MS risk and 564
dietary supplements 564–567, 569
differential diagnosis of MS 646
diffusion anisotropy 92
diffusion imaging 186–193
see also diffusion tensor imaging; diffusion weighted imaging
diffusion tensor imaging (DTI) 92, 186
basic principles 186–188
 correlations with atrophy 138
electrophysiological changes and 189
fiber tracking methods 186, 190–191
gray matter pathology 169, 189
histopathological changes and 189–190
in clinical practice 192
in clinical trials 192–193
201
lesion evolution 94, 188
MS studies 188–189
neuronal injury 536
pathway-specific measurements 190–192
tract based spatial statistics (TBSS) 189
voxel-wise comparisons (VWC) 189
diffusion weighted imaging (DWI) 187
dihydro-orotate dehydrogenase (DH-ODH) 410
dimethyl fumarate (DMF) 387–391, 542
adverse effects 389, 390–391
history 387–388
mechanisms of action 388–389
molecular structure 387
Phase 1 trial 388–389
Phase 2 trial 389–391
Phase 3 trials 391
preparations 387
disability
alemtuzumab-induced improvement 394–395
axonal hypothesis 151
axonal pathology and 150–151
 cortical lesions and 17, 168
depression and 696
as end-point 234–236
fatigue and 654
health psychology 56
medical model 56
MRI correlates
average lesion MTR 117
CNS atrophy 138–140
DTI-based pathway measures 191
enhancing lesions 98–99
T1-hypointense lesions 105–106
T2-hyperintense lesions 103
MRS correlates 156–157
neuromyelitis optica 616, 625
neuronal damage and 17–18
progression
IFNB studies 306
pediatric MS 632–633: see also progression of disease retinal nerve fiber layer thickness and 219
Social Security Administration (SSA) definition 57
vs. impairment 56
disability/impairment measures 4–5, 56–63
in clinical practice 590–591
methodological issues 57
scales 63, 234
selection 234
surrogate 58
see also Expanded Disability Status Scale; Multiple Sclerosis Functional Composite
discovery-driven research 272
conventional biomarkers and 274
see also -omics techniques; pharmacogenomics
disease-modifying therapies (DMT) 583–595
acute relapses 594
approved agents 583–589
assessing efficacy 233
children 595
clinically isolated syndromes 593
in combination see combination therapies elderly patients 595
fatigue and 654–655
fulminant MS 593–594
goals 583–585
health-related quality of life assessment 84
immunization and 716
limitations of currently available 589
long-term follow-up studies 8, 244–249
monitoring for efficacy 590–592, 649–650
criteria for change of agent 591–592
frequency 591
measures of disease activity 590–591
monitoring for tolerability and safety 584, 590
neuropsychological outcome studies 66–68
non-Caucasian populations 595
number needed to treat (NNT) 267
pediatric MS 595, 633–634, 638
in pregnancy 584, 595, 716–717
progressive MS 594–595
rational for early treatment 583–585
relapsing remitting MS 589–593
see also specific agents
dissemination of disease events in space (DIS) 645–648
dissemination of disease events in time (DIT) 645–648
Ditropan™ see oxybutinin
docosahexaenoic acid (DHA) 565
donepezil 68–69
Doppler ultrasonography 576, 578
dose–response designs 254
double-blind trials 265
double-filtration plasmapheresis (DFPP) 454–455, 459
adverse effects 460
double inversion recovery (DIR) imaging 166–169
doxazosin 683–684
doxepin 710–711
dronabinol (Mariiol) 568–569
drug development/approval 225–230
Asia 228–229
biosimilars 229
emerging topics 229–230
European Union 227–228
international cooperation 230
role of -omics research 274–275
United States 225–227
see also clinical trials; Food and Drug Administration; marketing authorization
DTI see diffusion tensor imaging
 duloxetine 700, 711–712
Dynamic Gait Index (DGI) 726
E2F pathway 278
EAE see experimental autoimmune encephalomyelitis
early-stage MS
CNS atrophy 134
ongoing tissue destruction 1–2
rationale for treatment 583–585
subclinical nature 1
timing of initiation of treatment 648–649
Early Treatment of MS (ETOMS) study 302–304, 585
EDSS see Expanded Disability Status Scale
education, patient 726–728
educational support, pediatric MS 639
efficacy of treatment clinical end-points see end-points, clinical comparative studies see comparative effectiveness studies
demonstrating long-term 244–249
MRI-based assessment 202
Index

fatigue 654–660
clinical features 654–656
definition 654
depression and 655, 697, 698
evaluation 658, 659
functional imaging 178–179
future research 660
in clinical practice 660
interferon beta-1a induced 179
measurement 656
medications causing 654–655,
720
pathogenesis 656–658, 720
pediatric MS 640
sexual dysfunction and 687, 689
treatment 658–660
Fatigue Scale 656
Fatigue Severity Scale (FSS) 656
FDA see Food and Drug Administration
female sexual dysfunction 689–690
FERMIMS study 352
fertility treatment 718
fear-related deterioration 511
fiber tracts
degeneration,
T2-hyperintensities 99, 104
tracking methods 186, 190, 191
fibrosis, nephrogenic systemic (NSF) 650
fingolimod 370–381, 588–589
brain atrophy changes 142,
377–378
clinical trials 370–371,
376–378
compared to IFNβ 309,
377–378
fulminant MS 593–594
in clinical practice 584, 590,
592, 593–594
in pregnancy and lactation 380,
716–717
mechanisms of action 372–373, 375–376, 485
neuroprotective effects 535
pediatric MS 638
pharmacology 371–374
primary progressive MS 371,
380, 607
retinal changes 220
safety and tolerability 374,
378–380, 588–589
target population 380
fish oil 564–565, 569
FK506 541
flax seed oil 564–565
flecainide 541
fluid-attenuating inversion recovery (FLAIR) 91
fluorodeoxyglucose positron emission tomography (FDG PET) 178
fluoxetine 700
flushing, dimethyl fumarate-induced 390–391
fluvoxamine 699
fMRI see functional magnetic resonance imaging
folic acid 437
Food and Drug Administration (FDA)
acceptance of
europsychological tests 74
approval of biosimilars 229
drug approval process 223–227, 239
fingolimod recommendations 374, 380
focus on post-marketing safety 229
on adaptive designs 257–258
on clinical utility of MSFC 61, 62
on health-related quality of
time measures 80, 84
on placebo-controlled studies 266
on surrogate end-points 58, 239
Transparency Initiative 229
Food and Drug Administration Amendments Act, 2007 (FDAAA) 229–230
fractional anisotropy (FA) 92,
187–188, 536
fractures, risk factors 718
FREEDOMS trial 371, 377, 380,
588
advocate events 378, 379, 380,
588–589
FREEDOMS II trial 371
FreeSurfer software 132
French/British mitoxantrone trial 345–346
FTY720 see fingolimod
fulminant MS see malignant MS
Fumaderm 387
Phase 1 trial 388–389
see also dimethyl fumarate
fumaric acid 387–388
see also dimethyl fumarate
Functional Assessment of Multiple Sclerosis (FAMS) 84–85
functional assessment tools 4–5,
58–63
in clinical practice 591
selection 233–235, 236
spasticity 667
see also disability/impairment
measures; Expanded Disability Status Scale; Multiple Sclerosis Functional Composite
developmental disability see disability
Functional Electrical Stimulation 727
functional imaging 175–182
fatigue 657
future directions 182
methods 173–178
MS-specific challenges 177–178
studies in MS 178–182
see also specific modalities
functional impairment see impairment
Functional Independence Measure (FIM) 57, 63, 726
functional magnetic resonance imaging (fMRI) 176–178
changes in MS 178–182
cogntive dysfunction 74,
180–181
DTI-based pathway measures
and 191–192
fatigue 178–179, 657
grey matter 170–171
in clinical trials 202
interpretation of cortical reorganization 181–182
motor function 179–180
MS-specific challenges 177–178
primary progressive MS 609
residing state (rMSFI) 176–177, 182
statistical analysis and image processing 177
task-dependent designs 176
visual dysfunction 180
GA see glatiramer acetate
GABA, markers of IFNβ
responsiveness 277
 gabapentin 669, 710–711, 720
gadolinium (Gad)–enhancement 91–92
limitations 94
pathophysiology 92–93
gadolinium (Gad)–enhancing lesions see enhancing lesions
gadolinium (Gad) contrast agents, safety 650
gamma linolenic acid (GLA) 564–565
γδ T cells 26, 29
GAMPP trial 450–452
gastrointestinal side-effects, dimethyl fumarate 390–391
GDx-VCC technology 220
gender
fatigue and 654
prognostic significance 49–50
gene expression studies 275
drug therapy response 276, 278–280
genes, candidate susceptibility 39, 275
genetics 35–43, 272–273
complexity 35–37
glossary 42–43
identifying high-risk families 40–42
immune-related risk factors 23
neuromyelitis optica 615–616
timeline of research 36
genome sequencing, full 41
genome-wide association studies (GWAS) 35, 38–39
defined 43
genotype-phenotype associations 38
susceptibility genes 39, 275
genomic expression studies see
gene expression studies
genomics 272
genotype-phenotype associations 38–40

© in this web service Cambridge University Press www.cambridge.org
human papillomavirus (HPV) vaccination 715
HuMax-CD20 see ofatumumab
humoral responses therapies targeting 483–485 see also antibodies; B cells
hydration, brain volume measurement and 134
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 465–466
inhibitors see statins
hyoscyamine 683
hypercholesterolemia 51
hypersensitivity reactions methylprednisolone 427–428
natalizumab 335, 337, 587
natalizumab antibodies 294
hypothesis 51
hypothalamic-pituitary-adrenal (HPA) axis, dysregulation 657
hypothyroidism 719–720
ibudilast 142, 542
Idevone 609
IFNβ RRMS study 302, 304
Ig-Therasorb 455
ileovescostomy 685–686
imaging neuromyelitis optica (NMO) 621–623
retinal 213–222
urinary tract 678–679 see also functional imaging; magnetic resonance imaging, other specific modalities
imipramine 682–683
immune cells natalizumab actions 330–331
routes of CNS invasion 22, 26–27
sphingosine 1-phosphate receptors 372
statin actions 467–468 see also B cells; lymphocytes; natural killer (NK) cells; T cell(s)
immune reconstitution inflammatory syndrome (IRIS) 338
immune thrombocytopenic purpura (ITP) 396
immunization 714–716 see also vaccination
immunoabsorption adverse effects 460–461
mechanism of action 459
natalizumab-associated PML 338, 339
neuromyelitis optica 459
techniques 454–455
immunoglobulins (Ig) pathogenic role in MS 491–492
rituximab–treated patients 488–490
role in CNS injury 27, 28
see also antibodies; intravenous immunoglobulin
immunology of MS 20–21, 29
axonal loss 13–14
CNS recovery, protection and repair 28–29
fatigue 657
framework 21–22
genetic and environmental risk factors 23
immune cell invasion of CNS 22, 26–27
innate immune responses 22–25
regulatory T cells 25
relationship to disease course 20–21
role of B cells 25–26
strength of autoimmune hypothesis 20–21
immunomodulatory drugs effects on cerebral atrophy and black holes 535
epidemiological studies 533–536
mitoxantrone as 344–345
neuroprotective effects 540
Immunosorb columns 455
immunosuppressive drugs 436–438, 441
effects on B cells 484, 485–486
hematopoietic stem cell transplantation 511
immunization and 716
mitoxantrone as 344–345
neuromyelitis optica 626–627
randomized trials 440 see also azathioprine; cyclophosphamide; methotrexate; mycophenolate mofetil
IMPACT study 303, 307–308
use of MSFC 61–63
impairment
axonal hypothesis 151
depression and 696
measures see disability/impairment measures vs. disability 56
impotence see erectile dysfunction
Imuran see azathioprine
in vitro fertilization (IVF) 718
Incacity Status Scale (ISS) 725
INCOMIN study 305, 308–309, 589
incomplete (urethral) sphincteric relaxation (ISR) 681–682
independent component analysis (ICA) 177
independent review, principle of 263
India, drug development/approval 228
individualized medicine see personalized medicine
infections after apheresis procedures 461
alemtuzumab-related 396
cladribine-related 363
dimethyl fumarate-related 391
fingolimod-related 374,
379–380, 588–589
mesenchymal stem cell transplant recipients 526
natalizumab-related 334–335, 337, 387–588
prevention see immunization relapse risk 714
rituximab-related 488
infertility treatment 718
inflammation
axonal damage 12–13, 151
cortical/grey matter lesions 15–16, 165
mechanisms 537–538
MRT visualization 92–94
as therapeutic target 17–18, 535–536
influenza vaccination 715–716
informed consent 225–226,
263–264
placebo-controlled trials 267
INFORMS study 371, 607
infusion reactions
alemtuzumab 395–396
mesenchymal stem cell transplantation 526
natalizumab 294, 335, 337
rituximab 488
injury, physical 707
innate immune system 22
innate-adaptive bridges 26
role in CNS injury 29
inosine 540
insomnia 720
institutional review boards (IRBs) 225–226, 263
instrumental variable analysis 248–249
insulin-like growth factor-I 540
insulin-like growth factor binding protein-3 540
integrins 473
see also α4β1 integrin
intercellular adhesion molecule-1 (ICAM-1) 467–468
interferon(s) (IFN) 300
interferon alpha (IFNα) 324
interferon beta (IFNβ) 300–311, 585–586
adverse effects 310, 585, 720
approved agents 584
binding antibodies (RBAs) 288
bioactivity, measurement 289–290, 293
biological effects 300–301
biomarkers of response 275, 301
DNA-based studies 276–277
gene expression studies 278–279, 301
metabolomics studies 280–282
observational studies 306, 310
proteomics studies 280, 281
brain atrophy changes 140–143
in clinical practice 589, 592
clinical trials 302–310
clinically isolated syndromes 302–304, 310, 593
combination studies 324
azathioprine 441
cyclophosphamide 437
glatiramer acetate 549–550
methotrexate 439
methylprednisolone 423–425, 428–429, 593
mitoxantrone 353
mycophenolate mofetil 439
natalizumab 335–337, 550–551, 593
statins 468
terifluromide 413–414
comparative trials 308–309
alemtuzumab 395
primary progressive MS 608
selection 589
interferon gamma (IFNγ) depressed patients 700
gene polymorphisms 277
glatiramer acetate effects 317
pathogenic role 473, 477
interferon gamma-inducible protein-10 (IP-10) 623
interferon receptors (IFNAR) 300–301
circulating soluble (IFNAR) 288
gene markers of response to therapy 276–277
interferon-sensitive response elements (ISRE) 301
interferon tau (IFNτ) 503
interleukin 2 receptor (IL-2R), daclizumab actions 399
interleukin 6 (IL-6) 538, 623
interleukin 10 (IL-10) glatiramer acetate and 316
IFNβ-treated patients 277, 290, 301
production in MS 25–26
interleukin 12 (IL-12), therapies targeting 476–477
interleukin 17 (IL-17) 473
interleukin 21 (IL-21) 396
internal jugular vein (IJV) 575
angioplasty 577–578
flow patterns in MS 576–578
International Classification of Functioning, Disability and Health (ICF) 724
International Conference on Harmonization (ICH) 230, 261, 266
International Ethical Guidelines for Biomedical Research Involving Human Subjects 261
International Multiple Sclerosis Genetics Consortium (IMSGC) 38–39
International Panel on the Diagnosis of MS 645–646, 647
intrathecal pumps 671
MRI safety 650
intravenous immunoglobulin (IVIG) 44–452
acute relapses 444–445
current recommendations 451–452
long-term treatment 446–451
mechanism of action 444, 483–485
neuromyelitis optica 627
pediatric MS 633, 638
post-partum use 449–450
in pregnancy and lactation 716–717
primary progressive MS 449, 608
reversal of fixed deficits 450–451
tolerability and safety 447–448, 452
intravesical medications 683–684
inverse probability of treatment weighting (IPTW) 247
investigational medicinal product dossier (IMPD) 227
investigational new drug (IND) application 225
iron deposition 574, 579
irritable bowel syndrome 51
ISP-1 (myriocin) 372
Italian studies glatiramer acetate 321
mitoxantrone in relapsing remitting MS 345
item response theory (IRT) 82–83
IVIG see intravenous immunoglobulin
JAK2 gene 277
JC virus 338, 339, 587
immunity, effects of natalizumab 339
measurement 339–340, 387
jugular vein see internal jugular vein
justice, principle of 262, 265
Kelch-like ECH-associated protein 1 (Keap-1) 388
ketamine cream 710–711
Kurtzke Expanded Disability Status Scale see Expanded Disability Status Scale
Kv channels 338
L-selectins 473
labeling, drug 226, 236
lactation see breast feeding
lamotrigine 15, 142–143, 541
laquinimod 405–408
mechanism of action 405–406
pharmacodynamics 406
Phase 2 clinical trials 406–407
Phase 3 clinical trials 408
safety and tolerability 407–408
latitudes 37
left ventricular ejection fraction (LVEF) 347–348, 350–351
lesions, MRI-defined 5, 91–92, 106
atypical see cortical lesions;
gray matter (GM) pathology clinical relevance 1, 6–7, 98–99, 103, 105–106
diffusion tensor imaging 188
diffusion weighted imaging 187–188
evolution 92–95
MT imaging 114–117
pathological significance 99, 103–104
tumefactive 95
typical, formation 92–93
see also enhancing lesions;
T1-hypointense lesions;
T2-hyperintense lesions;
white matter lesions
leukemia, mitoxantrone-related 351, 588
leukemia inhibitory factor (LIF) 540
leukocyte esterase test 678
leukocytes cladribine actions 366
cortical lesions 16
mitoxantrone actions 344–345
natalizumab actions 330–331
routes of CNS invasion 26–27
levetiracetam 711
Levitra™ see vardenafil
liberisation procedure 264, 580
libido, decreased 687, 690
lidocaine intravenous 711
patches 710–711
linear regression 247
Lingo 28, 543
linkage disequilibrium (LD) 43
linoleic acid 564–565
limonide (roquinimex) 405
Lioresal® see baclofen
lipidic acid (LA) 566, 569
lithium 541, 703
LMP7 gene 276–277
local anesthetics, spasticity 670
logistic regression 247
long-term treatment effects 8, 244–249
long-term follow-up studies (LTFUs) 245
non randomized observational trials (NROTs) 245–249
RCTs 244
lower urinary tract imaging 678–679
neural control 676
lower urinary tract dysfunction (LUTD) 676–686
clinical presentation 682–684
management 682–686
medications causing 677
uroanatomy 676–677
surgical management 684–686
luciferase assay 288–289
lung disease, chronic 51
Luvox see fluvoxamine
lymph nodes, CNS antigen drainage 23
lymphocytopenia 476
lymphocyte function-associated antigen-1 (LFA-1) 467–468
lymphocytes
alemtuzumab actions 394
cadribine actions 359–360
fingolimod actions 373–375, 379–380
mitoxantrone actions 344–345
natalizumab actions 330–331
reirculation 370
fingolimod actions 373–375
sphingosine 1-phosphate receptors 372
statin actions 467–468
see also B cells; immune cells; T cells(s)
lymphoid foci, formation of new 493
lymphoid follicle-like structures, meningeal 29, 493
lymphoma
primary CNS B-cell 588
rituximab 486
lymphopenia
alemtuzumab-induced 394
cadribine-induced 363, 366
fingolimod-induced 373
lymphotoxin (LT) 26, 29
matbhera© see rituximab
macrophages
fingolimod actions 405
patrogenic role 537–538, 565–566
T-cell activation 27
macula region of retina 213
changes in MS 215, 218
macular edema, fingolimod-induced 374, 379
magnetic Imaging in MS (MAGNIMS) committee 646, 648
magnetic resonance angiography (MRA) 578
magnetic resonance imaging (MRI)
advanced techniques see diffusion imaging; functional magnetic resonance imaging; magnetic resonance spectroscopy; magnetization transfer imaging
assessing neuronal injury 536
basic principles 91–92
in clinical practice 591, 645–651
diagnosis of MS 645–648
follow-up and monitoring
future prospects 650–651
in clinical trials 198–199, 208
CNS atrophy 7, 140–143, 200–202
conventional measures 5–6, 97–98, 101–102, 105, 199–200
diffusion tensor imaging
192–193, 201
exploratory measures 200–202
functional MRI 202
MR spectroscopy 158–159, 201
MT imaging 120–121, 201
Phase 1 trials 203
Phase 2 trials 203–204
Phase 3 trials 204
practical aspects 205–208
primary progressive MS 606
purposes 202–203
rational 198, 199
safety monitoring 98, 202–203
statistical aspects 204–205
clinically isolated syndromes 646–648
conventional (cMRI) 91–106
CNS atrophy see atrophy
CNS definition 92
gray matter pathology
94–95, 166–169
lesions see lesions, MRI-defined
limitations 112
monitoring lesion activity 95–98
normal-appearing white matter see
normal-appearing white matter techniques 91–92
use in clinical trials 5–6
diagnostic criteria 645–646
pediatric MS 632
differential diagnosis of MS 646
fatigue 657
high/ultrahigh field 95.
166–167, 169, 650
magnetic field strength 650
neuromyelitis optica 621–623
radiologically isolated syndrome (RIS) 648
safety 650
spinal cord 171–172, 648
magnetic resonance spectroscopy (imaging)
(MRS(I)) 92, 150–159, 536
correlations with atrophy 138
correlations with disability 156–157
diffusion tensor imaging and 189
evidence for axonal pathology 155
gray matter pathology 155, 168–170
histopathological correlates 155–156
in clinical trials 158–159, 201
lesion evolution 94
major resonances 152–154
primary progressive MS 606
role in MS 157–159
spinal cord 172
techniques 152–155
urine metabolites 280–282
magnetic resonance venography
(MRV) 579–580
magnetization transfer imaging
(MTI; MT-MRI) 579
methylprednisolone
average lesion 114, 147
contour plotting 114
high-dose methylprednisolone and 426
histogram analysis 114, 118–119, 201
maps 113–115
pathological correlates 113–116
region of interest (ROI) analysis 114
voxel-wise statistical analysis 114
MAGNIMS committee 646, 648
major histocompatibility complex see MHC
male sexual dysfunction 687–690
malignancies, secondary
alemtuzumab-related 396
azathioprine-related 411
cadribine-related 366
cyclophosphamide-related 438
fingolimod-related 380
mesenchymal stem cell transplant recipients 526
mitoxantrone-related 351, 588
natalizumab-related 338, 588
malignant MS
disease-modifying therapies 593–594
hematopoietic stem cell transplantation 514–515
mitoxantrone 349–349, 353
see also relapsing remitting MS (RRMS), aggressive
Marinol (dronabinol) 568–569
markers see biomarkers
marketing authorization
accelerated approval 226, 228, 239
application procedures 226–228
European centralized procedure 228
inspections of facilities 226, 228
international cooperation 230 maintaining the license 226–228
priority review 226
matching 246–247
matrix metalloproteinases (MMP)
fish oil supplements and 565 monitoring IFNβ response 278–280 pathogenic role 473, 537
statin actions 468
McDonald criteria 645–648
mean diffusivity (MD) 187–188
measles, mumps and rubella (MMR) vaccine 715
measurement tools
classes 57
clinical 4–5
clinically meaningful 237–238 complexities impacting clinical trials 4–6
development of new 236 disease-specific vs. generic 57 fatigue 656
health-related quality of life 5, 79–87
impairment and disability see disability/impairment measures
neuropsychological function 5, 65–74
rehabilitation outcomes 725–726
single- vs. multidimensional 57 see also end-points
cmoclebin 699
MECOMBIN study 423–425, 427, 550, 593
medical comorbidities 51–52, 714–721
medical model of disability 56
meditation 563
melanoma 338, 588
Mellen Center Gait Test 726
memantine 68, 69, 540
memory deficits 65
assessment 71–72
methylprednisolone-related 428
memory T cells 473
meningal inflammation 165
meningal lymphoid follicle-like structures 29, 493
meningococcal vaccine 715
mental illness 51 see also depression
mesenchymal stem cell transplantation (MSCT) 520–527, 543
allogenic, combined with HSCT 516–517
consensus recommendations 527
planned studies in MS 527
published studies in MS 525
rejection 526
safety issues 526–527
studies in other conditions 523, 525
mesenchymal stem cells (MSC) 509, 516, 520–521
ectopic tissue formation 526
effects on Th1/Th17 cells 25
factors affecting characteristics 524–525
immunomodulatory effects 516
immunoprivileged status 522–523, 526
in vitro immune effects 521–522
in vivo immunomodulatory effects 522
minimal criteria 520–521
neural repair potential 522–524
phenotypic characterization 520–521
trafficking after IV administration 524
metabolomics 272–273
studies in MS 290–282
metaxalone 711
methocarbamol 711
methotrexate 438–439
in clinical practice 594
effects on B cells 485
neuropsychological outcome 67
in pregnancy and lactation 716
primary progressive MS 608
randomized trials 439, 440
methylphenidate 659, 720
methylprednisolone (MP)
(including high-dose MP; HDMP) 418–429
acute relapses 420–422, 594
adverse effects 427–428, 720
in clinical practice 428–429, 593–594
 cyclophosphamide with 437–438
doses 421–422, 429
duration/frequency of therapy 421–422, 429
IFNβ neutralizing antibodies and 289, 423, 426–427
imaging studies 424–426
in pregnancy and lactation 716–717
intravenous (IVMP) 418
intravenous immunoglobulin with 445
mechanism of action 418–420
mitoxantrone with 346, 348, 349
MRI studies 204, 425–426
neuromyelitis optica 625
optic neuritis 422, 426
oral administration 418
pediatric MS 633, 638
pharmacology 418–420
primary progressive MS 608
progressive MS 594
relapsing MS 419–424, 428–429
acute disease course impact 422–423
relapses 420–422
chronic disease course impact 423–425
history 420
imaging studies 425–426
routes of administration 421–422, 429
secondary progressive MS 421, 424–425, 428–429
MHC
alleles, MS susceptibility 23, 37–38
class II
glatiramer acetate binding 316
statin actions 467
molecules, structural equivalence 24
microarray studies see gene expression studies
microglia
CNS recovery and repair 29
cortical lesions 15–17
laquinnom actions 406
role in CNS injury 29, 537–538
T-cell activation 27
microRNA (miRNA) 25, 275
milnacipran 711
MIMS study 346–348, 352
mind–body therapies 563–564
mindfulness-based stress reduction (MBRS) 563
mindfulness training 640, 658
Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) 71–72
Minimal Record of Disabilities for MS (MRD) 725
minocycline
glatiramer acetate combination 325
neuroprotective effects 541
mirtazepine 700
MIST trial 515–516
mitoxantrone (mitox) 344–353, 588
adverse effects 345–352, 588
clinical role 352–353
early clinical trials 345
glatiramer acetate combination 324–325, 349
in clinical practice 384, 589–590, 593, 594
in pregnancy and lactation 716
induction therapy 348–349, 353
mechanisms of action 344–345, 484–485
neuromyelitis optica 627
pediatric MS 637
pharmacokinetics 345
Phase 2 trials 345–346
Phase 3 trial (MIMS) 346–348
post-approval studies 348–349
preliminary uncontrolled studies 345
primary progressive MS 348, 352, 608
tolerability 349–352
trials supporting regulatory approval 345–348
MMP see matrix metalloproteinases
mobility problems, pediatric MS 639
modafinil 720
mood dysfunction 68–69
fatigue 658–659
pediatric MS 640
Modified Ashworth Scale (MAS) 667
Modified Fatigue Impact Scale (MFIS) 656
molecular mimicry 21–24, 473
monoclonal antibodies, therapeutic antibodies against 293–295
history of development 393
see also alemtuzumab; daclizumab; natalizumab; rituximab
monocytes, glatiramer acetate actions 316
motor deficits, fixed, IVIG therapy 450
motor fatigability 656
motor system, functional imaging 179–180
MRI see magnetic resonance imaging
MRS see magnetic resonance spectroscopy
MS-001 study 359–360
MS Genetic Burden (MSGB) 41–42
MS-Scrpps study 359–360
MSCRG IFNβ study 302, 306, 309
MSFC see Multiple Sclerosis Functional Composite
MSIS-29 see Multiple Sclerosis Impact Scale
MT imaging see magnetization transfer imaging
MT-MRI see magnetization transfer imaging
MTI see magnetization transfer imaging
MTR see magnetization transfer ratio
mucosal (oral) tolerance 475
multiple imputation method 249
Multiple Sclerosis Functional Composite (MSFC) 4–5, 59–63, 236
in clinical practice 591
cognitive component 71, 237
as composite outcome 255
correlation with CNS atrophy 138–139
development 59–60
interpretation of results 61–62, 237
potential improvements 62–63, 237–238
primary progressive MS 606
rehabilitation 725
Z-score 60, 237
Multiple Sclerosis Impact Scale (MSIS-29) 63, 725
primary progressive MS 606
randomized clinical trials using 84–85
Multiple Sclerosis Quality of Life Health Survey-54 (MSQOL-54) 85–86
Multiple Sclerosis Quality of Life Inventory (MSQLI) 84–85
Multiple Sclerosis Severity Scale (MSSS) 59
Multiple Sclerosis Spasticity Scale (MSSS-88) 667
Multiple Sclerosis Walking Scale (MWSW-12) 726
multipotent stromal cells see mesenchymal stem cells
muscle spasms 709, 710
see also spasticity
musculoskeletal comorbidities 51
musculoskeletal pain syndromes 707–708
pathophysiology 707–708
muscle atrophy 709, 710
MxA induction assay 288, 293
MxA protein 278, 289–290
mycoplasmol motefil 438–439
adverse effects 627
effects on B cells 484
neuromyelitis optica 439, 626–627
myelin antibodies targeting 28, 491–492
autoantigens in MS 316
loss see demyelination
oral therapy 475
myelin-associated glycoprotein (MAG) 14, 539
myelin basic protein (MBP) 315–316
altered peptide ligands and 474
antibodies 492
myelin oligodendrocyte glycoprotein (MOG) 28, 316
antibodies 491–492
myelitis
recurrent, plasma exchange 456–457
transverse see transverse myelitis
myeloid cells 26–27
myricin 372
myxovirus resistance protein A see MxA protein
N-acetyl-containing compounds (NA)
brain changes in MS 152, 155
clinical disability 156–157
clinical remission 157
measurement 152–154
monitoring treatment effects 158–159
N-acetylaspartate (NAA)
brain changes 152, 155
genetic influences 40
glatiramer acetate studies 318
gray matter 168–170
interpreting changes 154
measurement 152–154
spinal cord changes 172
use in clinical trials 201
N-acetylaspartylglutamate (NAAG)
interpreting changes 154
measurement 152–154
NA/Cr ratio (or NAA/Cr ratio)
changes in MS 153
clinical disability 156–157
clinical remission 157
high-dose methylprednisolone and 426
measurement 154
role in clinical trials 158–159, 201
NAA see N-acetylaspartate
nabiximols (Sativex) 670, 683
naltrexone, low dose 568–569
neuroprotective effects 541
spasticity 670
β-naphthoflavone 542
narcolepsy 720–721
narcotic analgesics 711–712
natalizumab 300–341, 586–588
adverse effects 334–335, 337, 338, 587–588
antibodies 293–295, 335, 587
-associated PML see under progressive multifocal leukoencephalopathy
brain atrophy changes 140
in clinical practice 340–341, 584, 589, 592–593
combination therapy 550–551
glatiramer acetate 325, 337–338, 551
IFNβ 335–337, 550–551, 593
discontinuation 340, 587
Fab-arm exchange with IgG4 331–332
gene expression studies 279
health-related quality of life effects 86–87
markers of response 281
mechanism of action 330–331, 484–485
monitoring patients on 340
neuroprotective effects 535
neuropsychological effects 67
pediatric MS 636–637
pharmacokinetics and pharmacodynamics 331–332
Phase 1 studies 332
Phase 2 studies 332–333
Phase 3 registration studies 333–338, 340
post-marketing studies 338
pre-registration studies 332–333
preclinical studies 331
in pregnancy and lactation 716–717
see also AFFIRM study;
SENTINEL trial
National Bioethics Advisory Commission (NBAC) 268
National Institutes of Health (NIH), fatigue measure 656
National Multiple Sclerosis Society (NMSS) Task Force 59–60, 254, 267–268
natural history of MS 47, 48
immune pathogenesis 20, 21
primary progressive MS 47
relapsing onset MS 47
temporal trends 47, 249
see also progression of disease
natural killer (NK) cells 26, 29
daclizumab actions 26, 399
laquinimid actions 406
mesenchymal stem cell effects 522
nausea and vomiting
mitoxantrone-induced 352
neuromyelitis optica 621–623
NBI-5788 474
NCT00001934 trial 401
NCT01143441 trial 400, 403
negative binomial regression 205
neopterin 280–282, 290
nephrogenic systemic fibrosis (NSF) 650
neural autoantibodies, neuromyelitis optica 624
neural stem/precursor cells 508, 520
stimulating function of endogenous 542–543
transplantation 542
neuro-orthopedic surgery 671
Neuro-QOL 82–83, 87, 724, 726
neurodegeneration mechanisms 537–539
see also axonal loss/pathology; neuronal damage
neurogenic detrusor hyperactivity see detrusor hyperreflexia
neuroimmunophilin ligands 541
Neurological Fatigue Index (NFI-MS) 565
neurolysis, chemical 670
neuromyelitis optica (NMO) 4, 614–615, 627
associated autoimmune diseases 623–624
biomarker 616–617
brain lesions 621–623
clinical features, course and prognosis 616
CSF testing 623
diagnostic criteria 615
epidemiology 614–616
clinical genetics 613–616
immunopathology 618–619
mycophenolate mofetil 439, 626–627
neural autoantibodies 624
neuroimaging 621–623
new perspective 614
optical coherence tomography 216, 221–222
paraneoplastic 624–625
pathogenesis 618–621
plasma exchange 455–460, 625
traditional view 614
treatment 625–627
see also anti-aquaporin-4 antibodies
neuronal damage compensation for 17
cortical lesions 15–17
functional consequences 17–18
mechanisms 537–539
methods of assessment 536–537
optical coherence tomography 217–220
prevention see neuroprotection
T-cell mediated 27
see also axonal loss/pathology
neurons, fingoilmod actions 375–376
Neurontin® see gabapentin
neuropathic pain, treatment 710–711
neuroplasticity 725
neuroprotection 535–543
candidate drugs 540–542
clinical trials in MS 539–540
corticosteroids 419
dimethyl fumarate 388
glatiramer acetate 318, 535, 540
growth factors 540
strategies 15, 539
study designs 7, 540
neuroprotective autoimmunity 395
neuropsychological (NP) assessment 5, 65–74
adequacy of single test 71
choice of tests 71
classified tests 71–72
disease-modifying therapy trials 66–68
factors complicating 68–70
future directions 74
in clinical practice 591
practice effects 68–70, 72–73
quality of data 73
rational 66
recommendations 71–74
sensitivity to change 68
statistical analysis of data 73–74
symptomatic therapy trials 68–70
neuroregenerative strategies 542–543
neurosurgical interventions, spasticity 672
neutralizing antibodies (NAbs) 295
IFNβ see interferon beta 293–295, 335
other monoclonal antibodies 295
pharmacogenomics studies 275–276
neuropenia, mitoxantrone induced 352
new drug application (NDA) 226, 239
nine-hole peg test (9HPT) 60, 591
nitric oxide (NO)
IFN-treated patients 280–282
role in CNS injury 13, 537
nitrile test 678
NMO see neuromyelitis optica
NMO/AQP4-IgG see anti-aquaporin-4 antibodies
nocturnia, management 683–684, 720
Nogo A protein 28
non-arteritic anterior ischemic optic neuropathy (NAION) 221
non-inferiority studies 256, 269
non parametric statistical methods 203
non randomized observational trials see observational trials
Nordic SPMS study 303, 307
normal-appearing brain tissue (NART), MT imaging 118–119
normal-appearing white matter (NAWM)
axonal loss 156
diffusion tensor imaging 188
diffusion weighted imaging 188
MRS 94, 152, 155
functional significance 157
MT imaging 94, 116, 118–119
NORMIMS trial 423–425, 550, 593
Nofopram see desipramine
North American Research Committee on Multiple Sclerosis (NARCOMS) Registry 46, 49, 51
North American SPMS study 303–304, 307–308
nortriptyline 700, 711
Novantrone see mitoxantrone
Nrf2 (nuclear factor E2-related factor 2) 388, 542
nuclear magnetic resonance spectroscopy (NMR) see magnetic resonance spectroscopy
5’-nucleotidase (5’-NTase) 358–359
Nuffield Council on Bioethics 268
number needed to treat (NNT), current therapies 267
numerical rating scale (NRS), spasticity 667
Nuremberg Code (1947) 261
obesity 719
observational trials (non randomized; NROTIs) 8, 245–249
adjusting for bias and confounding 246–248, 249
hidden biases 249
optimizing 249
sources of bias and confounding 246
vs. RCTs 245, 249
obstructive sleep apnea 721
ocrelizumab 489
mechanisms of action 485, 490–491
OCT see optical coherence tomography
ofatumumab 485, 489–490
older patients aging-related brain volume changes 134
disease-modifying therapies 595
olfactory ensheathing cells (OECs) 542
oligoclonal bands (OCBs) 491, 623
oligodendrocyte precursor cells (OPCs) 542
enhancing remyelination potential 542–543
transplantation 542
oligodendrocytes 14
fingoilmod actions 375
olive oil 564–565
omega-3 fatty acids 564–565, 569
mood disorders 703
omega-6 fatty acids 564–565, 569
omics techniques 272–273, 282–283
conventional biomarkers and 274
role in drug development 274–275
see also metabolomics; pharmacogenomics; proteomics
ONWARD studies 367, 550
opiates 711–712
optic nerve, MT imaging 120
optic neuritis (ON) 120
chronic multiple sclerosis 211–222
functional imaging 180
intravenous immunoglobulin 445
methylprednisolone 422, 426, 429
MT imaging 113, 120
neuromyelitis optica 614, 616
treatment of acute attacks 625
NMO (AQP4)-IgG 617
optical coherence tomography 214, 217–220, 356
visual pathway axonal loss 216–217
Optic Neuritis Treatment Trial (ONTT) 422, 429
optic neuritis 120
chronic multiple sclerosis 211–222
non-arteritic anterior ischemic optic neuropathy (NAION) 221
occult 217
optic-spinal MS (OSMS) see neuromyelitis optica
optical coherence tomography (OCT) 213–222
in clinical practice 591
differential diagnosis 221–222
features and advantages 213–214, 215, 218
Fourier (spectral) domain 215–217, 220, 536
quality of data 219–220
role in MS 214–215, 217–220, 536–537
three-dimensional (3D) 220
OPTIMS study 304
ORACLE trial 367
oral contraceptives 501, 718
drug interactions 718
oral disease-modifying agents 387
glatiramer acetate 325, 475
pediatric MS 638
see also dimethyl fumarate;
 fingolimod; laquinimod;
teriflunomide
oral tolerance 475
ordinary least squares method 255
orthogonal arrays of particles (OAPs)
orthopedic surgery 671
orthoses 727
osteogenesis imperfecta 524
osteopenia 718
osteoporosis 718
corticosteroid-induced 428
risk factors 718
outcome measures see end-points
ovariectomy 499
overdispersed data 205
OWIMS study 302, 304–305
oxidative stress 537–538,
565–566
oxybutin 682–683, 720
intravesical 683
transdermal patch (Oxytrol®) 682–683
paced auditory serial addition test (PASAT) 60, 68, 71,
237
in clinical practice 591
pain 707–712
acute 707
definition 708
depression associated with 708–709

treatment 712
fatigue and 655
management 709–712
neuropathic 710–711
pathophysiology 707–708
psychological aspects 708–709
parallel diffusivity (k||) 187
parenchymal fraction (PF) 130
paroxetine 699, 700, 712
pathology 12–18
cortical lesions 15, 16–17
functional consequences 17–18
future challenges 18
heterogeneity 3–4
MRI correlates 536
diffusion tensor imaging 189–190
enhancing lesions 99
magnetization transfer 113–116
normal–appearing white matter 118
T1-hypointense lesions 106
T2-hyperintense lesions 99, 103–104
MRS correlates 155–156
neuromyelitis optica 618–619
primary progressive MS 604
progressive destructive, early-stage disease 1–2
subclinical, early-stage disease 1
see also axonal loss/pathology;
neuronal damage
Patient Determined Disease Steps 63
patient-reported outcomes (PROs) 57, 63, 234, 238
quality of life 79
spasticity 667
Paxil see paroxetine
pediatric MS 632–640
acute relapses, treatment 633
anti-myelin antibodies 492
clinical presentation and course 632–633
definitions 632
disease-modifying therapies 595, 633–634, 638
first-line agents 633–635
second-line agents 636–638
treatment failure 635–636
psychosocial care and symptomatic therapies 638–640
spinal cord imaging 621
therapies 640
pediatric patients
drug development 225, 227
ethics of research 262
pemoline 70
pendulum test 667
penile injection therapies 688, 689
penile prostheses 688–689
percent brain parenchyma volume (PBV) 130
percentage brain volume change (PBVC) 131
performance measures 57, 234
Periactin® see cyproheptadine
Periodic Adverse Experience Reports 226
peripheral blood stem cells (PBSCs) 308–310
peripheral vascular disease 51
personalized medicine 8, 272, 275
PET see positron emission tomography
pharmacogenetics (PGt) 272–274
pharmacogenomics (Pgmx) 272–283
changing definition 272–273
conventional biomarkers and 274
MS studies 275–279
need for predictive biomarkers 272–273
related disciplines/technologies 272, 274
role in drug development 274–275
see also -omics techniques
Phase 1 trials
adaptive designs 257
combination therapies 548–549
end-points 233
risk–benefit ratio 262–263
role of MRI 203
Phase 2 trials
adaptive designs 257
combination therapies 549
end-points 198, 233
use of MRI 203–204
Phase 3 trials
adaptive designs 257
combination therapies 549
end-points 198, 233
use of MRI 204
phenotypic heterogeneity 2
phenytoin 15, 540–541
phosphocreatine 154
phosphodiesterase-5 inhibitors 687–688, 690
physical activity see exercise
physical deconditioning 658, 709
physical treatments, spasticity 668
physostigmine 69
pifarnidone 608
placebo-controlled trials 253–255
alternative study designs 254, 269–270
eqipoupo and 265–267
ethical issues 254, 265–267, 270
specific problems 253–254
virtual placebo 254–255, 269
see also randomized controlled trials
plaques 12
see also lesions, MRI-defined
plasma cells, within CNS 29
plasma exchange (PLEX) 454–462
adverse effects 460–461
current recommendations 454–455
mechanism of action 459–460, 483–485
natalizumab-associated PML
338, 339, 457
neuromyelitis optica see under
neuromyelitis optica
pediatric MS 633
technique 454–455
use in CNS demyelinating
disease 455–459
plasmapheresis
double-filtration (DFPP)
454–455, 459–460
see also plasma exchange
plasticity, neural 725
PML see progressive multifocal
leukoencephalopathy
PMS see progressive MS
pneumococcal vaccine 715
Poser criteria 645
positron emission tomography (PET) 176
cognitive dysfunction 180
fatigue 657
studies in MS 178
post-marketing safety monitoring 8
FDA requirements 226
increased focus 229
role of MRI 98, 202–203
post-partum period
hormonal changes 504
intravenous immunoglobulin 449–450
relapses 498
see also breast feeding
post-void residual (PVR) 677
measurement 678
posterior rhizotomy, selective 672
posterior tibial nerve stimulation, percutaneous 684
potassium (K⁺) channel blockers 538, 557
see also dalfampridine
potassium channels, voltage gated (Kv) 538
PPMS see primary progressive MS
PPMS IFN-β-1a Study 303
practice effects, neuropsychological (NP) tests 68–70, 72–73
prazosin 684
PreCiSe trial 320
predictive biomarkers (of response to therapy) 275–279
genotype-related studies 275–276, 278
need for 272–273
RNA based studies 276, 278–280
prednisone acute relapses 594
cyclophosphamide with 436–437
neuromyelitis optica 625, 627
optic neuritis 422
pregabalin 711
pregnancy 498–504, 716–717
animal models of MS 499
cladribine safety 366
disease-modifying therapies 584, 595, 716–717
effect on MS 498–499
factors with therapeutic potential 499–504
fingolimod safety 380, 716–717
hormone-assisted 718
immunology 499
management of relapses 717
MRI during 650
teriflunomide safety 415
Pregnancy in MS (PRIMS) study 449, 498, 504
PREMIERE study 367
Prevention of Relapse with IVIG (PRIVIG) trial 448–449, 451
primary progressive MS (PPMS) 2, 604–609
characteristics 604–605
clopidrine 607
ethics of clinical trials 267
fingolimod 371, 380, 607
future therapeutic approaches 609
glatiramer acetate 320, 607
IFNβ 303, 607–608
implementing therapeutic trials 605–606
intravenous immunoglobulin 449, 608
mitoxantrone 348, 352, 608
MRI studies 604
CNS atrophy 135–136, 606
enhancing lesions 97, 99, 606
magnetization transfer 118–119, 606
T1-hypointense lesions 105
T2-hyperintense lesions 101, 606
natural history 47–48
pathological features 604
problems in studying 2–3
riluzole 608
rituximab 487–488, 607
therapeutic agents 594–595, 606–608
PRIMS (Pregnancy in MS) study 449, 498, 504
PRISMS study 291, 302, 304
long-term follow-up 306, 309–310
PRIVIG trial 448–449, 451
Profile of Mood States 656
progesterone (progesterone) changes in pregnancy 499
treatment 352, 499, 501, 504
prognostic factors 47–50, 52
additional 49–52
study design issues 3
traditional 47–49
progression of disease 47–48
biological mechanisms 20–21
biomarkers 41–42
conventional MRI monitoring 95–98
DTI-measured changes 193
effect of neutralizing antibodies 292, 293
measures 4–6
pediatric MS 632–633
see also natural history of MS
progressive MS (PMS) alemtuzumab 394
cladribine 360
cyclophosphamide 436–437, 594
disease-modifying therapies 594–595
glatiramer acetate 319, 594
IFNβ 303–304
methotrexate 439, 594
mitoxantrone 345–348, 352–353, 594
MRI monitoring 650
myoclonic epilepsy 439
neuropsychological outcome studies 66–67
plasma exchange 455, 457–458
see also primary progressive MS
progressive MS
secondary progressive MS
progressive multifocal leukoencephalopathy (PML)
immunosuppressed patients 438–439
myoclonic
methotrexate-related 627
natalizumab-related 330, 337–341
in clinical practice 587
monitoring for 340, 587
plasma exchange 338, 339, 457
protection 340, 587
treatment 338–340, 587
rituximab-related 488
progressive relapsing MS (PRMS) 3, 604
disease-modifying therapies 594–595
see also primary progressive MS
prokarin 658–659
prolactin 504
PROMISE trial 320, 607
propensity score (PS) technique 247–248
proportional hazard regression 247
propensity score adjustment 248
propylpyrazoletriol (PPT) 500, 502–503
prospective markers 273
protein tyrosine kinase (PTK), inhibition 410
proteinases, neurotrophic 537
proteolipid protein (PLP) 14, 316
proteomics 272, 273
studies in MS 280–282
proton density 91
proton magnetic resonance spectroscopy (imaging) (1H-MRS(I)) 150–159
see also magnetic resonance spectroscopy
pseudoatrophy, brain see brain pseudoatrophy
pseudoexacerbations 511, 677
psychological aspects of pain 708–709
psychological effects, high-dose
methylprednisolone 427
psychosocial care, caregivers 701–702
pediatric MS 638–640
psychotherapy 699, 712
pulmonary side-effects, fingolimod 374, 379
pyrimidines, inhibition of
synthesis 410
qi gong 563
quality-adjusted life years (QALY) 81
quality of life (QOL) definition 724
health-related see health-related quality of life
racial differences disease-modifying therapy responsiveness 595
neuromyelitis optica 615
prognosis 49–51
radial (transverse) diffusivity (λ) 187–188
radiation, myeloablative 511
radiologically isolated syndrome (RIS) 648
random-effects regression modeling 73
randomization adaptive 235–256
defered 256
prevention of bias 244, 249
response adaptive 256
role of MRI 98, 202
unbalanced 254
randomized controlled trials (RCTs) 244, 249
alternative designs 253–258
ethical issues 254, 265–270
long-term 244
long-term follow-up (LTFU) after 245
monitoring, in clinical practice 590
MRI-defined enhancing lesions and 98
neuromyelitis optica, predictive biomarker 617
neutralizing antibodies and 291–293
as outcome measures 235
insensitivity 1
limitations 6
pain associated with 708–709
pediatric MS 632
pregnancy-related effects 498–499
prevention see disease-modifying therapies
prognostic significance 49
psychosocial stress and 700
rates 4
limitations 6
long-term outcome and 6
natural history studies 47
subjectivity of measuring 6
vaccination during 714
relapsing onset MS (R-MS)
natural history 47–48
see also relapsing remitting MS; secondary progressive MS
relapsing–remitting MS (RRMS)
aggressive hematopoietic stem cell transplantation 514–515
mitoxantrone 348, 353; see also malignant MS
Alemtuzumab 394–395
Azathioprine 441
Cladribine 359–360
Cyclophosphamide 437
Daclizumab 399–400, 402
Dimethyl fumarate 388–391
Disease-modifying therapies 589–593
choice of agent 589–590
clinical management 590–592
improving compliance 590
options for continued disease activity 592–593
Fingolimod
in clinical practice 590, 592
clinical trials 371, 376–378, 380
Glatiramer acetate
in clinical practice 589, 592
clinical trials 318–320, 321–324, 325
Hematopoietic stem cell transplantation 514–515
IFNβ
in clinical practice 589, 592–593
clinical trials 302, 304–307, 309–310
intravenous immunoglobulin 444–449
Laquinimod 406–407
Methotrexate 439
Methylprednisolone 419–426, 428–429
Mitoxantrone
in clinical practice 589–590
clinical trials 345–349, 353
MRI studies
CNS atrophy 134–136, 138
enhancing lesions 96–97
T1-hypointense lesions 105
T2-hyperintense lesions 101
MRS studies 157
MT imaging 117–119
mycophenolate mofetil 439
Natalizumab 330–341, 589, 592–593
Natural history 47
Neuropsychological outcome studies 66–67
Ocrelizumab 489
Optical coherence tomography 219
Rituximab
as rescue therapy 353
‘window of therapeutic opportunity’ concept 394
Reliability
atrophy measurements 129
quality of life measures 82
REM sleep behavior disorder 721
Remission
biological mechanisms 20
MRS studies 157
Remyelination
enhancing potential of endogenous stem cells 542–543
immune mechanisms 28, 29
MT imaging 113, 115, 121
Therapies 15
Renal complications 682
Renal imaging 678
Renuel study 350, 351
Repair mechanisms, CNS 28, 29
Reproducibility
atrophy measurements 129
DTI measurements 192–193
Optical coherence tomography 219
Reproductive dysfunction cladribine-related 366
Mitoxantrone-related 351–352
Reproductive health 716–718
Resiniferatoxin, intravascular 683–684
Respect for potential and enrolled subjects 264
Response-adaptive randomization 256
Response to therapy, predictive biomarkers see predictive biomarkers
Restless legs syndrome 721
Resveratrol 541–542
Retinal atrophy 220
Retinal imaging 213–222
Future prospects 220–221
see also optical coherence tomography
Retinal nerve fiber layer (RNFL) 213
Changes over time 219
Clinical significance of thinning 218–219
Measuring thickness 214, 216
MS and optic neuritis 214, 217–218, 536
Neuromyelitis optica 221–222
Rheumatoid arthritis (RA)
Combination therapies 548
Ocrelizumab 489
Rituximab 486
Rho 468
Isoprenylation 465, 466, 467
Riluzole 541, 608
Risk-benefit ratio, trial participants 262–263, 268
Risk evaluation and mitigation strategy (REMS) 230
Risk factors, immune mechanisms 23
Rituxan® see rituximab
Rituximab 486–489
Antibodies 295, 489
Autologous hematopoietic stem cell transplantation 511
B-cell reconstitution after 491
Intrathecal 490, 493
Lymphoma and autoimmune disease 486
Mechanisms of action 485, 490–491
Neuromyelitis optica 626, 627
Pediatric MS 637
Pharmacodynamics 488–489
Primary progressive MS 487–488, 607
relapsing remitting MS 486–487
safety and tolerability 488
rivastigmine
cognitive dysfunction 68, 69, 74
functional imaging 181
RIViLSe study 490
roquinimex 405
RORγ (RORC) 24–25
RRMS see relapsing remitting MS
safety monitoring
ethical aspects 263
post-marketing see post-marketing safety monitoring
role of MRI 98, 202–203
SaGAs (Short and Graphic Assemblies) 260
salmeterol (albuterol) 477
sample size
based on enhanced lesions 98
cognitive efficacy studies 256
designs to reduce 255
primary progressive MS 605
Sanctura™ see trospium
Sativex (nabiximols) 670, 683
Schumacher criteria 645
Schwann cell transplantation 542
scientific validity of research 262, 268
scientific value of research 261–262
Scripps-C study 359–360
Scripps Neurological Rating Scale 63
secondary progressive MS (SPMS)
daclizumab 399–400
anti-tNF-α and TNF-α inhibitors 303, 304, 307–308, 311, 594
intravenous immunoglobulin 444–445, 449
laquinimod 406–407
methylenepridolone 421, 424, 425, 428, 429, 594
mitoxantrone 345–348, 349, 352–353, 594
MRI
CNS atrophy 134–135, 136
enhancing lesions 96, 97
magnetization transfer 117, 118, 119
monitoring 650
T2-hyperintense lesions 101
MRS studies 157
natalizumab 332–333
natural history 47, 48
study design issues 2–3
threshold model 1–2
seizures, dalfampridine-related 560
SELECT study 400, 403
selection, subject
fairness 262
role of MRI 202
selection bias 246
selective estrogen receptor modulators 500–501, 502, 503
selective serotonin reuptake inhibitors (SSRIs) 699, 700
pediatric MS 639–640
self-assessment measures 57, 63
fatigue 656
see also patient-reported outcomes
sensitivity analysis 249
SENTINEL trial 336–337, 550–551, 587, 593
anti-tNF-α and TNF-α inhibitors 294, 297
health-related quality of life outcomes 86–87
sertraline 699, 700
severity, disease biomarker in neuromyelitis optica 617–618
declining, in contemporary trials 7
standard MRI measures 200
study design issues 3
sex hormones 499–501
see also estrogen(s);
progesterone
sexual counseling 687, 688, 690
sexual dysfunction 676, 686–690
evaluation 687, 689–690
female 689–690
male 687–689
treatment 687–688, 689, 690
SF-36 83, 86–87
fatigue measurement 656
rehabilitation settings 726
Sickness Impact Profile 86, 656
SIENA 131, 132, 133
SIENAX 131
sildenafil 687–688, 690
SIMCOMBIN trial 550
simvastatin 468
single nucleotide polymorphisms (SNPs) 35, 38, 39
defined 43
discordant twin pairs 41
glatiramer acetate response 276
IFNβ response 276–277
weighted log-additive integrative approach 41, 42
single photon emission computed tomography (SPECT) 176, 178
cognitive dysfunction 180
depression 179
Spjøgren syndrome 623–624
skeletal health 718–719
sleep disordered breathing (sleep apnea) 721
sleep disorders 655, 658, 720–721
medications causing 720
SM3 397
smoking, tobacco 52, 719
Social Security Administration (SSA), definition of disability 57
social value of research 261–262, 268
sodium (Na+) channel blockers 15, 538, 541
sodium (Na+) channels 14–15, 151, 538
sodium pump (Na+/K+ -ATPase) 14–15
solifenacin 683
somatic cell nuclear transplantation 543
spasm frequency scale 667
spasticity 666–672
assessment 666–667
clinical features 666
intrathecal medications 671–672
local treatments 670–671
neurosurgical interventions 672
oral medications 668–670
pain 709
pathophysiology 666
pediatric MS 639
sexual dysfunction 687
treatment 667–672, 710
SPECT see single photon emission computed tomography
SPECTRIMS study 303–304, 307
spinchterotomy, urethral 685
sphingosine 1-phosphate (SIP) 370–372
functions 370, 375–376
mechanisms of action 371–372
sources 370
sphingosine 1-phosphate receptors (S1PR) 371–372
CNS cells 372, 375
fingolimod actions 373, 374–375, 376
immune cells 372
sphingosine kinase (SphK) 370
spinal cord
assessing neuronal injury 336
gray matter pathology 171–172
imaging 171–172
diagnosis of MS 648
neuromyelitis optica 621
longitudinally extensive lesion 621
MT imaging 119–120
evaluation 618–619
sacral lesions 676
suprasacral lesions 676–677
T1-hypointense lesions 105
spinal cord atrophy
clinical significance 139–140, 606
in clinical trials 201–202
measurement methods 133
natural history 134
spinal cord stimulators, MRI safety 650
spinal venous system
anatomy 575–576
chronic insufficiency see chronic cerebrospinal venous insufficiency
SPM software 131–132
SPMS see secondary progressive MS
standard gamble 81
standard of care
resource-limited countries 268
universal 267–268
statins 465–469, 540
combination therapy in MS 468–469
experimental CNS autoimmune 465–468
Index

statins (cont.)
immunomodulatory properties 465–466
mechanism of action 465–466
MS therapy 468–469
toxicities 469

statistical analysis
adaptive study designs 257–258
alternative study designs 257–258
EDSS data 58–59
functional MRI data 177
MRI-based outcome measures 204–205
neuropsychological test data 73–74
observational trials 247–249

STATs 301
stem cell transplantation
potential issues in MS 527
preventing rejection 543
primary progressive MS 609
remyelination studies 542–543
see also hematopoietic stem cell transplantation;
mesenchymal stem cell transplantation
stem cells 508–510, 520
adult 508–509
embryonic (ESC) 508–509, 520
hematopoietic see hematopoietic stem cells
mesenchymal see mesenchymal stem cells
peripheral blood (PBSCs) 508–510
stimulating function of endogenous 542
therapeutic use 542–543
steroids see corticosteroids
stratification 247
stress, psychosocial 698, 700
structural equivalence 24
subclinical disease activity 1
subgroup analysis, neuropsychological outcome data 74
suicide 697–698
sulfatase modifying factor 1 (SUMF1) gene variant 38–40
sunflower seed oil 564–565, 569
superiority studies 256, 269
suprapubic cystostomy 684–685
surrogate endpoints 58, 232
biomarkers as 239–241
pharmacogenomics approach 274–275
to reduce trial size and duration 256–257
survival analysis 73–74
Swank diet 564
Symbol Digit Modalities Test (SDMT) 71
symptomatic therapies
assessing efficacy 233
neuropsychological outcome studies 68–70
pediatric MS 638–640
rehabilitation approach 727
systemic lupus erythematosus (SLE) 623–624
T cell(s)
avtivation 472, 474, 537
within CNS 27, 473
autoactive 21–22
antigens activating 22–24
evidence for involvement 22–23
regulatory mechanisms 25–26
vaccination strategies 475
co-stimulation 24
differentiation into subsets 24–25
drugs affecting
alemtuzumab 394
anti-CD20 antibodies 490–491
cyclophosphamide 436
dacizumab 399
dimethyl fumarate 388
fingolimod 373–375, 379–380
glatiramer acetate 316–318
laquinimod 405–406
mitoxantrone 344–345
tatistatin 467–468
teriflunomide 410–411
see also T-cell based therapies
γδ 26, 29
glatiramer acetate-specific 316–318, 475
mechanisms of CNS injury 27
t Mesenchymal stem cell effects 521
migration into tissues 472–473
pathogenic role 472, 474, 537
recirculation 370
phosphatidic 1-phosphate receptors 372
vaccination 475
see also CD4+ helper T cells; CD8+ cytotoxic T cells;
immune cells; lymphocytes; regulatory T cells
T-cell based therapies 472–477
affecting B cells 484–486
cytokine modulation 476–477
drugs with secondary effects 477
rational 472
specific targets 472–473
targeting specific T cells 474–476
targeting T cells non-specifically 476
see also T cell(s), drugs affecting
T-cell receptors (TCR) 472
hematopoietic stem cell transplantation and 510
vaccination targeting 475–476
T helper cell subsets see Th1 cells; Th2 cells; Th3 cells; Th17 cells
T helper cells see CD4+ helper T cells
T1 burden of disease 104–105
DTI-based pathway measures and 191
measurement 106
T1-hypointense lesions (T1 black
holes) 5, 92, 104–106
acute and chronic 103, 105
behavior over time 105
clinical significance 105–106
correlations with atrophy 137
effects of immunomodulatory drugs 535
effects on atrophy
measurements 134
evolution 93–94, 105
monitoring therapy 105, 200
MT imaging 116
pathological significance 106, 536
techniques of measuring 106
volume see T1 burden of disease
T1-relaxation time (T1-RT)
measurements, gray matter 170
T1-weighted images 91
tadalafil 687–688
tai chi 563–564
talampanel 541
Tardieu scale 667
TARIMS study 444–445
Tbet 24–25
TEMSO trial 413
tensor-based morphometry (TBM) 131
TERACLES trial 414
terazosin 683–684
teriflunomide 410–416
adjunctive therapy trials 413–414
chemical structure 410
clinical development program 412–416
mechanism of action 410–411
monotherapy trials 412–413
pharmacokinetikis 411–412
preclinical studies 411
safety 414–415
testosterone 690
tetanus diphtheria and acellular pertussis (TDap/TD)
vaccine 715–716
tetrahydrocannabinol (THC),
primary progressive MS 608
tetrahydrocannabinol-
cannabidiol (THC-CBD) 568–569
see also cannabinoids; Sativex
Th1 cells
laquinimod actions 405
pathogenic role 24–25, 473, 499
pregnancy-related changes 499
regulatory control 26
statin actions 467
Index

vitamin D 23, 37, 718–719
cancer 719
changes in pregnancy 504
metabolomics studies 280
treatment 52, 504, 719
vitamin D binding protein (VDBP) 280
vitamin E 567
VLA-4 see α4β1 integrin
voiding
neural control 676
timed/double 684
voiding cystourethrogram 678–679, 681
voiding dysfunction
evaluation 677–682
see also bladder dysfunction
vomiting see nausea and vomiting
voxel-based morphometry (VBM) 131
voxel-wise comparisons (VWC) 189
vulnerable populations, ethics of research 262, 267–268
walking performance
effects of dalfampridine 558–560, 727
measures 236, 726
water channel autoimmunity 614
white matter (WM)
atrophy
clinical significance 138–140
measurement 131–132
rates 136
treatment effects 143
dirty appearing 116
normal appearing see normal-appearing white matter
white matter (WM) lesions
conventional MRI 92–94
correlations 156
correlations with atrophy 136–137
differential diagnosis 646
diffusion tensor imaging 188
effects on atrophy measurements 134
formation 92–93
MRS findings 155
MRS–histopathology correlations 156
MT imaging 114–117
see also enhancing lesions; lesions, MRI-defined;
T1-hypointense lesions;
T2-hyperintense lesions
white matter pathways
functional correlates of DTI measures 190–192
identification using DTI 186, 190–191
whole-brain studies
diffusion tensor imaging 188–189
MT imaging 119, 201
see also brain atrophy
whole-genome association studies (WGA), pharmacogenomics 277
Will Rogers phenomenon 249
“window of therapeutic opportunity” concept 394
within-subject designs, adjusting for bias 246
World Health Organization (WHO) 724
XAF-1 278
yoga 563
yohimbine 687–688
z statistics, combined 255
Zanaflex® see tizanidine
ZAPMS study 400, 402
Zenapax® see daclizumab
Zoloft see sertraline